Methods for non-invasive determination of advancement of liver fibrosis

Česká verzia

Authors: M. Koula; M. Hrůzová; D. Harmáček; P. Hříbek; A. Černá; D. Dvořáková; P. Urbánek
Authors place of work: Interní klinika 1. LF UK a ÚVN Praha
Published in the journal: Gastroent Hepatol 2016; 70(2): 118-124
Category: Hepatology: Review article
doi: https://doi.org/10.14735/amgh2016118

Summary

Prognosis, care, and treatment of chronic liver diseases greatly depend on the degree and rate of progression of hepatic fibrosis. For many years, histological evaluation has been the gold standard for measuring the advancement of liver fibrosis. Liver biopsy is an invasive method, the serial repetition of which in a single patient raises a number of problematic issues, including ethical ones. Therefore, much effort has been devoted to finding a non-invasive procedure. A very promising method in recent years involves the evaluation of liver elasticity. These elastography-based methods use shear waves propagating through hepatic tissues to measure liver elasticity. The principle of elastography itself has been known for many decades, but has only been applied in the last decade in the development of devices capable of providing a diagnosis in hepatology.

Key words:
liver fibrosis – cirrhosis – elastography – Fibroscan^® – shear-waves

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
15. 3. 2016

Accepted:
2. 4. 2016

Zdroje

1. Castera L, Pinzani M. Non-invasive assessment of liver fibrosis: are we ready? Lancet 2010; 375(9724): 1419–1420. doi: 10.1016/S0140-6736(09)62195-4.

2. Rockey C, Caldwell SH, Goodman ZD et al. Liver Biopsy. Hepatology 2009; 49(3): 1017–1044. doi: 10.1002/hep.22742.

3. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24(2): 289–293.

4. Imbert-Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357(9262): 1069–1075.

5. Castera L, Vilgrain V, Angulo P. Non-invasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10(11): 666–675. doi: 10.1038/nrgastro.2013.175.

6. European Association for the Study of the Liver. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatology 2015; 63(1): 237–264. doi: 10.1016/j.jhep.2015.04.006.

7. Castera L. Noninvasive assessment of liver fibrosis. Dig Dis 2015; 33(4): 498–503. doi: 10.1159/000374097.

8. Jeong WK, Lim HK, Lee HK et al. Principles and clinical application of ultrasound elastography for diffuse liver disease. Ultrasonography 2014; 33(3): 149–160. doi: 10.14366/usg.14003.

9. Castéra L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128(2): 343– 350.

10. Castéra L, Foucher J, Bernard PH et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51(3): 828–835. doi: 10.1002/hep.23425.

11. Myers RP, Pomier-Layrargues G, Kirsch R et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55(1): 199– 208. doi: 10.1002/hep.24624.

12. Mederacke I, Wursthorn K, Kirschner J et al. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int 2009; 29(10): 1500–1506. doi: 10.1111/j.1478-3231.2009.02100.x.

13. Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29(12): 1705–1713.

14. Berzigotti A, Castera L. Update on ultrasound imaging of liver fibrosis. J Hepatol 2013; 59(1): 180–182. doi: 10.1016/j.jhep.2012.12.028.

15. Castéra L Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142(6): 1293– 1302. doi: 10.1053/j.gastro. 2012.02.017.

16. Poynard T, Morra R, Halfon P et al. Metaanalyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40.

17. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38(2): 518–526.

18. Leroy V, Monier F, Bottari S et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004; 99(2): 271–279.

19. Adams LA, Bulsara M, Rossi E et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51(10): 1867–1873.

20. Calès P, Oberti F, Michalak S et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42(6): 1373–1381.

21. Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45(4): 846–854.

22. Castéra L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128(2): 343– 350.

23. Ziol M, Handra-Luca A, Kettaneh A et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41(1): 48–54.

24. Fraquelli M, Rigamonti C, Casazza G et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56(7): 968–973.

25. Corpechot C, El Naggar A, Poujol-Robert A et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006; 43(5): 1118–1124.

26. Foucher J, Chanteloup E, Vergniol Jet al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55(3): 403–408.

27. European Association for the Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63(1): 237–264. doi: 10.1016/j.jhep.2015.04.006.

28. Arena U, Vizzutti F, Abraldes JG et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008; 57(9): 1288–1293. doi: 10.1136/gut.2008.149708.

29. Nobili V, Vizzutti F, Arena U et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48(2): 442–448. doi: 10.1002/hep.22376.

30. Nahon P, Kettaneh A, Tengher-Barna Iet al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol 2008; 49(6): 1062– 1068. doi: 10.1016/j.jhep.2008.08.011.

31. Chan HL, Wong GL, Choi PC et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009; 16(1): 36– 44. doi: 10.1111/j.1365-2893.2008.01037.x.

32. Zarski JP, Sturm N, Guechot J et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012; 56(1): 55– 62. doi: 10.1016/j.jhep.2011.05.024.

33. Carrión JA, Navasa M, Bosch J et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006; 12(12): 1791– 1798.

34. Vizzutti F, Arena U, Romanelli RG et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45(5): 1290–1297.

35. Bureau C, Metivier S, Peron JM et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther 2008; 27(12): 1261–1268. doi: 10.1111/j.1365-2036.2008.03701.x.

36. Shi KQ, Fan YC, Pan ZZ et al. Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int 2013; 33(1): 62– 71. doi: 10.1111/liv.12003.

37. Llop E, Berzigotti A, Reig M et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol 2012; 56(1): 103–108. doi: 10.1016/j.jhep.2011.06.027.

38. Reiberger T, Ferlitsch A, Payer BA et al. Non-selective beta-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. J Gastroenterol 2012; 47(5): 561–568. doi: 10.1007/s00535-011-0517-4.

39. Vizzutti F, Arena U, Romanelli F et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45(5): 1290– 1297.

40. Kazemi F, Kettaneh A, N’Kontchou G et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol 2006; 45(2): 230–235.

41. Crespo G, Lens S, Gambato M et al. Liver stiffness 1 year after transplantation predicts clinical outcomes in patients with recurrent hepatitis C. Am J Transplant 2014; 14(2): 375– 383. doi: 10.1111/ajt.12594.

42. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60(2): 392– 420. doi: 10.1016/j.jhep.2013.11.003.

43. Friedrich-Rust M, Nierhoff J, Lupsor M et al. Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat 2012; 19(2): 212–219. doi: 10.1111/j.1365-2893.2011.01537.x.